Results 221 to 230 of about 244,171 (297)

Pre‐Existing Nocturia Status Predicts Bladder Symptom Exacerbation Following COVID‐19 Vaccination in Women

open access: yes
The Kaohsiung Journal of Medical Sciences, EarlyView.
Hsien‐Che Ou   +3 more
wiley   +1 more source

The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu   +6 more
wiley   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang   +5 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

open access: yesPhytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee   +9 more
wiley   +1 more source

Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Background and Aim New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)—protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin
Liqian Chen   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy